Houte Hans Van Sells 20,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 20,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now owns 31,002 shares of the company’s stock, valued at $781,870.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Thursday, August 1st, Houte Hans Van sold 3,477 shares of Nurix Therapeutics stock. The stock was sold at an average price of $21.45, for a total transaction of $74,581.65.
• On Tuesday, July 30th, Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30.

Nurix Therapeutics Stock Performance

NRIX stock opened at $25.09 on Thursday. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $26.12. The stock’s 50 day simple moving average is $21.50 and its 200 day simple moving average is $16.63. The company has a market cap of $1.23 billion, a P/E ratio of -8.59 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The business had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. Equities analysts predict that Nurix Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Barclays upped their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Oppenheimer upped their price objective on shares of Nurix Therapeutics from $25.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lifted their target price on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Piper Sandler restated an “overweight” rating and issued a $35.00 target price on shares of Nurix Therapeutics in a report on Wednesday, June 5th. Finally, Stephens assumed coverage on Nurix Therapeutics in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.69.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Nurix Therapeutics in the second quarter worth approximately $578,000. Driehaus Capital Management LLC purchased a new stake in Nurix Therapeutics in the 2nd quarter valued at $26,778,000. The Manufacturers Life Insurance Company raised its position in Nurix Therapeutics by 25.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock valued at $479,000 after buying an additional 4,583 shares during the last quarter. Millennium Management LLC lifted its stake in Nurix Therapeutics by 60.2% during the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after acquiring an additional 225,374 shares in the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in Nurix Therapeutics during the 2nd quarter worth $201,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.